Walleye Capital
ABBV icon

Walleye Capital’s AbbVie ABBV Stock Holding History

Walleye Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$332K Sell
1,321
-108,684
-99% -$23.4M ﹤0.01% 3090
2026
Q1 		$23.9M Sell
110,005
-60,736
-36% -$13.5M 0.1% 145
2025
Q4 		$39M Sell
170,741
-15,506
-8% -$3.53M 0.12% 99
2025
Q3 		$43.1M Buy
186,247
+2,429
+1% +$495K 0.16% 79
2025
Q2 		$34.1M Buy
183,818
+66,255
+56% +$12.3M 0.13% 94
2025
Q1 		$24.6M Buy
117,563
+116,476
+10,715% +$22.6M 0.11% 153
2024
Q4 		$193K Sell
1,087
-1,857
-63% -$341K ﹤0.01% 3782
2024
Q3 		$581K Sell
2,944
-99
-3% -$18.5K ﹤0.01% 3154
2024
Q2 		$522K Sell
3,043
-19,160
-86% -$3.17M ﹤0.01% 3478
2024
Q1 		$4.04M Buy
+22,203
New +$3.83M 0.01% 1450
2023
Q4 		– Sell
-15,889
Closed -$2.32M – 4873
2023
Q3 		$2.37M Sell
15,889
-4,704
-23% -$691K 0.01% 1599
2023
Q2 		$2.77M Buy
+20,593
New +$3.02M 0.01% 1102
2022
Q4 		– Sell
-36,910
Closed -$5.66M – 3122
2022
Q3 		$4.95M Sell
36,910
-12,005
-25% -$1.72M 0.09% 233
2022
Q2 		$7.49M Buy
+48,915
New +$7.47M 0.21% 100
2022
Q1 		– Sell
-6,081
Closed -$823K – 2250
2021
Q4 		$823K Sell
6,081
-72,913
-92% -$8.61M 0.03% 701
2021
Q3 		$8.52K Buy
+78,994
New +$9.03M 0.24% 37
2020
Q2 		– Sell
-1,778
Closed -$135K – 590
2020
Q1 		$135K Buy
1,778
+708
+66% +$60.3K 0.03% 526
2019
Q4 		$95K Buy
1,070
+480
+81% +$39.8K 0.01% 1372
2019
Q3 		$45K Buy
590
+310
+111% +$21.3K ﹤0.01% 1622
2019
Q2 		$20K Hold
280
– – ﹤0.01% 1526
2019
Q1 		$23K Buy
+280
New +$22.9K ﹤0.01% 1330

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Walleye Capital's ABBV Position: Q2 2026 in Review

Walleye Capital reduced its AbbVie (ABBV) stake by 99% in Q2 2026, selling an estimated $23.4M and leaving 1,321 shares worth $332K. The position accounts for ﹤0.01% of the portfolio, ranked #3090.

Walleye Capital first reported a position in ABBV in Q1 2019 and has held it in 21 quarters since. The position peaked at $43.1M in Q3 2025. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Walleye Capital held 1,321 shares of AbbVie worth $332K as of Q2 2026.
  • Walleye Capital sold 108,684 AbbVie shares in Q2 2026, an estimated $23.4M.
  • AbbVie made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3090 holding.
  • Walleye Capital first reported a position in AbbVie in Q1 2019 and has held it in 21 quarters since.
  • Walleye Capital's AbbVie position peaked at $43.1M in Q3 2025.
  • 4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.